Inhaled antibiotics are drugs administered through inhalation for the treatment of respiratory infections such as cystic fibrosis, bronchiectasis, and pneumonia. Inhaled antibiotics offer advantages over conventional antibiotic delivery through oral or intravenous administration such as direct delivery to the site of infection, use of lower drug doses, and fewer systemic side effects.

The global Inhaled Antibiotics Market is estimated to be valued at US$ 1,403.3 Mn  in 2023 and is expected to exhibit a CAGR of 6.7%  over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Rising prevalence of respiratory infections coupled with increasing product approvals is expected to drive the growth of the global inhaled antibiotics market over the forecast period. For instance, according to the Cystic Fibrosis Foundation, in the US, around 30,000 people are living with cystic fibrosis and about 1,000 new cases of CF are diagnosed each year.

One of the key drivers of the market is rising product approvals. For instance, in March 2022, Insmed Incorporated received the US FDA approval for Breyanzi (ilisimab) for the treatment of nontuberculous mycobacterial (NTM) lung infections in adult patients with cystic fibrosis. Breyanzi is the first therapy approved specifically for treatment of NTM lung infections in people living with cystic fibrosis (CF) in the US. The product approval is expected to increase the availability of treatment options and drive the growth of the market over the forecast period.

SWOT Analysis

Strength: The inhaled antibiotics market has strengths such as opportunities for targeted delivery and direct administration to the site of infection. This can result in higher efficacy with fewer side effects compared to oral or intravenous administration. It also allows for lower drug dosage and improves patient compliance as inhalation is less invasive.

Weakness: However, the market faces weaknesses such as the requirement of specialized devices and equipment for administering inhaled antibiotics. This increases costs and complexities. There is also a lack of variety in product offerings currently and regulatory hurdles in approval processes.

Opportunity: The market has opportunities for growth in developing innovative inhaled formulations of existing drugs as well as novel inhaled antibiotics. There is also opportunity to expand indications beyond cystic fibrosis and treat other respiratory infections. Further, increasing incidence of drug-resistant bacterial infections and aging population presents an opportunity.

Threats: Some threatsinclude requirement of large investments in R&D for drug development and device design. Further, entry of generic competitors once patents expire can impact market shares. The marketalso faces threats from alternative drug delivery forms and rising demand for therapeutics targeting specific disease pathways.

Key Takeaways

The global Inhaled Antibiotics Market Growth is expected to witness high growth over the forecast period owing to rising prevalence of chronic respiratory diseases along with growing antibacterial resistance. The market size for inhaled antibiotics was valued at US$ 1,403.3 Mn  in 2023 and is anticipated to reach over US$ 2,528.7 Mn by 2030, expanding at a CAGR of 6.7% .

Regional analysis: The North American region currently dominates the market and is expected to continue leading due to growing approval and adoption of new drugs. For instance, Aradigm Corporation gained approval for Linhaliq (cystic fibrosis) in the US. Meanwhile, Asia Pacific is predicted to see fastest growth on account of expanding patient pool, increasing awareness as well as robust economic development in many countries.

Key players: Key players operating in the inhaled antibiotics market are Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Teva Pharamceuticals, Altan Pharmaceuticals, Raptor Pharmaceutical Corp., Cipla Limited, Maya Biotech Pvt. Ltd., Medisol Lifescience Pvt. Ltd., Nivon Specialties, Sentiss Pharma Pvt. Ltd., Ultratech India Limited, Midas Care Pharmaceuticals Pvt Ltd., Precept Pharma Ltd., Luckys Pharma, and Pharmaxis Ltd.

Get More Insights On This Topic:  https://blogger-veritas.blogspot.com/2023/12/the-global-inhaled-antibiotics-market.html